AGL 38.10 Decreased By ▼ -0.06 (-0.16%)
AIRLINK 136.75 Increased By ▲ 2.56 (1.91%)
BOP 9.22 Increased By ▲ 0.37 (4.18%)
CNERGY 4.75 Increased By ▲ 0.06 (1.28%)
DCL 8.83 Increased By ▲ 0.16 (1.85%)
DFML 38.44 Decreased By ▼ -1.34 (-3.37%)
DGKC 85.40 Increased By ▲ 0.25 (0.29%)
FCCL 35.35 Increased By ▲ 0.45 (1.29%)
FFBL 76.99 Increased By ▲ 1.39 (1.84%)
FFL 12.70 Decreased By ▼ -0.04 (-0.31%)
HUBC 108.79 Decreased By ▼ -0.66 (-0.6%)
HUMNL 14.74 Increased By ▲ 0.64 (4.54%)
KEL 5.55 Increased By ▲ 0.15 (2.78%)
KOSM 8.05 Increased By ▲ 0.30 (3.87%)
MLCF 40.70 Decreased By ▼ -0.67 (-1.62%)
NBP 71.40 Increased By ▲ 1.70 (2.44%)
OGDC 194.75 Increased By ▲ 1.13 (0.58%)
PAEL 27.00 Increased By ▲ 0.79 (3.01%)
PIBTL 7.48 Increased By ▲ 0.06 (0.81%)
PPL 167.95 Increased By ▲ 4.10 (2.5%)
PRL 26.25 Decreased By ▼ -0.11 (-0.42%)
PTC 20.40 Increased By ▲ 0.93 (4.78%)
SEARL 92.84 Increased By ▲ 8.44 (10%)
TELE 7.89 Decreased By ▼ -0.10 (-1.25%)
TOMCL 35.32 Increased By ▲ 1.27 (3.73%)
TPLP 8.98 Increased By ▲ 0.26 (2.98%)
TREET 17.34 Increased By ▲ 0.16 (0.93%)
TRG 59.50 Decreased By ▼ -1.50 (-2.46%)
UNITY 31.00 Increased By ▲ 2.04 (7.04%)
WTL 1.39 Increased By ▲ 0.02 (1.46%)
BR100 10,895 Increased By 118.9 (1.1%)
BR30 32,660 Increased By 426.2 (1.32%)
KSE100 101,357 Increased By 1274.6 (1.27%)
KSE30 31,488 Increased By 295 (0.95%)

A popular antibiotic used for treating bronchitis, pneumonia, ear infections and sexually transmitted diseases may boost the risk of death, a US study said on May 16.
Azithromycin has been on the world-wide market since the 1980s, but the study in the New England Journal of Medicine is the first to document serious heart risks - up to a 2.5-fold higher chance of cardiovascular fatalities - in the first five days of treatment compared to another or no antibiotic.
The comparison was based on an examination of patient records in the southern US state of Tennessee from 1992 to 2006. Researchers at Vanderbilt University compared about 348,000 prescriptions of azithromycin to millions of records from people who were not treated with any antibiotics or who received amoxicillin, a similar medication that is considered heart safe. The analysis found there were 47 more deaths per million in those taking azithromycin compared to those on amoxicillin.
When researchers examined patients already at high risk for heart problems, the chance increased to 245 additional cardiovascular deaths per million in the azithromycin group compared to the amoxicillin takers. While the relative number of fatalities was low, researchers said the findings offer new information about possible dangers that doctors and patients should consider.
"We believe this study adds important information on the risk profile for azithromycin," said lead author Wayne Ray, professor of preventive medicine at Vanderbilt University.
"For patients with elevated cardiovascular risk and infections for which there are alternative antibiotics, the cardiovascular effects of azithromycin may be an important clinical consideration."
The Croatian pharmaceutical company Pliva first patented azithromycin in 1981, and later struck a world-wide deal with Pfizer to sell the antibiotic world-wide. Pfizer branded the treatment Zithromax and Zmax.
Azithromycin is a macrolide antibiotic that works by stopping the growth of bacteria. Side effects may include skin rashes, itching, swelling, difficulty breathing or swallowing and rapid, pounding or irregular heartbeats, according to the American Hospital Formulary Service.

Copyright Agence France-Presse, 2012

Comments

Comments are closed.